Immuneering Corp Total Liabilities
Immuneering Corp total liabilities. Based on the latest financial reports, Immuneering Corp (IMRX) has total liabilities worth $13.08 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Immuneering Corp liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Immuneering Corp (2019–2024)
Total liabilities of Immuneering Corp from 2019 to 2024. This chart illustrates how Immuneering Corp's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Immuneering Corp to see how much of total assets are deployed in long-term investments.
Immuneering Corp Competitors by Total Liabilities
The table below lists competitors of Immuneering Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jena Acquisition Corporation II
NYSE:JENA
|
USA | $14.61 Million |
|
Eisen- und Hüttenwerke AG
F:EIS
|
Germany | €2.12 Million |
|
Lanzhou Zhuangyuan Pasture Co Ltd
SHE:002910
|
China | CN¥1.24 Billion |
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
USA | $7.21 Million |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
Germany | €3.09 Billion |
|
KS Terminals Inc
TW:3003
|
Taiwan | NT$1.82 Billion |
|
Trigold Holdings Ltd
TWO:3709
|
Taiwan | NT$21.32 Billion |
|
Cogelec SA
PA:ALLEC
|
France | €95.77 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Immuneering Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IMRX asset base.
Liquidity & Leverage Metrics
Immuneering Corp Total Liabilities Ratios Explained
Immuneering Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immuneering Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immuneering Corp (2019–2024)
The table below shows the annual total liabilities of Immuneering Corp from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.33 Million | -5.66% |
| 2023-12-31 | $12.01 Million | -4.06% |
| 2022-12-31 | $12.52 Million | +16.71% |
| 2021-12-31 | $10.72 Million | -82.39% |
| 2020-12-31 | $60.90 Million | +195.27% |
| 2019-12-31 | $20.63 Million | -- |
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more